China Makes a Big Move in Pharma: Approves the Narcolepsy Treatment Revolutionizing the Field Before the U.S. and Europe

China has approved oveporexton for patients aged 16 and older with type 1 narcolepsy, ahead of the U.S., Europe, and Japan.

The oral selective orexin receptor 2 agonist significantly reduced excessive daytime sleepiness and cataplexy in international trials.

The decision gives patients a new targeted option for a chronic condition that has lacked disease-specific treatment.